Zydus Enters Agreement with CVS Caremark to Add Zituvio, Zituvimet
Zydus Lifesciences Ltd., a global innovation driven healthcare company, announced that it has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet XR (sitagliptin|sitagliptin and metformin hydrochloride) tablets to its template formulary.
CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025.
Zituvio and combination products include Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the US FDA earlier through the 505(b)(2) route. The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
Punit Patel, president & CEO Zydus Pharmaceuticals USA Inc., commented on the development, saying, ""We are proud to have partnered with CVS Caremark, one of the most patient-centric healthcare solutions providers in the US, to further our commitment to improving access to high-quality medications to patients and meeting their healthcare needs with reduced outlays. This relationship is a strong validation of Zydus’ strategic investments in 505(b)(2) portfolio and will set the way for further strengthening our portfolio of differentiated products in the US market."
Metabolic and lifestyle conditions, such as diabetes have been a significant contributor to prescription drug growth over the last decade.
According to IQVIA (MAT Aug-2023), US market for DPP-IV inhibitors and their combinations is US$ 10 billion.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!